+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Australian Female Infertility Diagnosis And Treatment Market 2019-2025

  • ID: 5013379
  • Report
  • January 2020
  • Region: Australia
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • Bayer AG
  • Church & Dwight Co., Inc.
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • Genea Ltd.
  • GlaxoSmithKline Plc.
Australian Female Infertility Diagnosis And Treatment Market Size, Share & Trends Analysis Report, By Diagnosis (Ovulation Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Ovarian Reserve Testing, Hormonal Level Testing, Genetic Testing, and Others (Laparoscopy)), By End-User (Hospitals and Clinics, Homecare, and Pathology and Diagnostic Centers), and Forecast, 2019-2025.

Australian female infertility diagnosis and treatment market is expected to witness a significant growth with the CAGR of 3.8% during the forecast period. The inability to conceive may occur in both men and women, however, infertility among women is more common. There are several factors that cause infertility among women such as exceeding 35 years of age, unhealthy lifestyle and genetic disorders. The market is driven by the growth in the number of infertility cases along with the extensive development of advanced technologies such as Assisted Reproductive Technology (ART) and Intrauterine Insemination (IUI).

In addition, the female infertility diagnosis and treatment diagnosis and treatment market are also growing due to the increasing trend of surrogacy, inclination towards in-vitro fertilization (IVF) treatment and rising population of women marrying in the late 30s. Change in the lifestyle among women is also considered as the major factor that tends to affect female fertility. The consumption of inadequate diet and body weight plays a major role in growing infertility among women. Overweight or underweight is one of the factors that affect the hormone production and affect the ovulation process.

Australian female infertility diagnosis and treatment market is segmented on the basis of diagnosis, treatment type, and end-user. Based on the diagnosis, the market is segmented into ovulation testing, hysterosalpingography (HSG), hysteroscopy, imaging testing, ovarian reserve testing, hormonal level testing, genetic testing, and others (laparoscopy). Based on the treatment type, the market is segmented into drugs, surgery, intrauterine insemination (IUI), and assisted reproductive technology (ART). Based on the end-user, the market is segmented into hospitals and clinics, homecare, and pathology and diagnostic center.

Some of the major players operating in the Australian female infertility diagnosis and treatment market include Abbott Laboratories, Inc., Merck KGaA, Cipla Ltd., and others. These players adopt various organic and inorganic growth strategies such as merger and acquisition and product launch to strengthen their presence in Australian market.

Research Methodology

The market study of the Australian female infertility diagnosis and treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for existing companies and new entrants into the market, potential investors and venture capitalists, government organizations, and various end-user industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the company and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Australian Female infertility diagnosis and treatment Market Research and Analysis by Diagnosis
2. Australian Female infertility diagnosis and treatment Market Research and Analysis by Treatment
3. Australian Female infertility diagnosis and treatment Market Research and Analysis by End-User

The Report Covers:
  • Comprehensive research methodology of Australian Female infertility diagnosis and treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting Australian Female infertility diagnosis and treatment market.
  • Insights about market determinants which are stimulating Australian Female infertility diagnosis and treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Church & Dwight Co., Inc.
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • Genea Ltd.
  • GlaxoSmithKline Plc.

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight& Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Australian Female Infertility Diagnosis And Treatment Market by Diagnosis
5.1.1. Ovulation Testing
5.1.2. Hysterosalpingography (HSG)
5.1.3. Hysteroscopy
5.1.4. Imaging Testing
5.1.5. Ovarian Reserve Testing
5.1.6. Hormonal Level Testing
5.1.7. Genetic Testing
5.1.8. Others (Laparoscopy)
5.2. Australian Female Infertility Diagnosis And Treatment Market by Treatment
5.2.1. Drugs
5.2.2. Surgery
5.2.3. Intrauterine Insemination (IUI)
5.2.4. Assisted Reproductive Technology (ART)
5.3. Australian Female Infertility Diagnosis And Treatment Market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Homecare
5.3.3. Pathology and Diagnostic Centers
6. Company Profiles
6.1. Genea Ltd.
6.2. Bayer AG
6.3. Pfizer
6.4. Merck KGaA
6.5. Church & Dwight Co., Inc.
6.6. Vitrolife
6.7. Cook Medical, Inc.
6.8. Eli Lilly & Co.
6.9. GlaxoSmithKline Plc.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Genea Ltd.
  • Bayer AG
  • Pfizer
  • Merck KGaA
  • Church & Dwight Co., Inc.
  • Vitrolife
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.
Note: Product cover images may vary from those shown